Quantcast

Latest Hodgkin's lymphoma Stories

2014-04-29 04:21:45

- First and Only Approved Monotherapy in the EU for this Patient Population - BIRMINGHAM, England, April 29, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54(th) annual scientific meeting of the British Society for Haematology. PIXUVRI...

2014-04-24 08:33:54

Patent covers methods of use for small molecule inhibitors in the treatment of NHL, including follicular and diffuse large B-cell lymphomas CAMBRIDGE, Mass., April 24, 2014 /PRNewswire-USNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted a notice of allowance for U.S. Patent Application...

2014-04-08 12:31:36

Community Leaders throughout the North Bay Area Assemble to Join LLS in the Fight against Blood Cancers SANTA ROSA, Calif., April 8, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter is launching its 2014 North Bay Man & Woman of the Year (MWOY) fundraising campaign, enlisting influential and compassionate community leaders as candidates competing to raise funds for blood cancer research and cures. In its second year, the North...

2014-04-08 08:30:17

Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients...

2014-04-02 12:31:39

New Program Brings Busy Moms Together to Get In Shape, Meet Other Moms and Raise Funds to Help Fight Cancer SAN FRANCISCO, April 2, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter has launched Moms In Training, a brand new nine-week workout program geared towards helping busy moms prepare for a 5K race, while meeting other moms in their community and raising funds for LLS's mission to fight blood cancer. Moms In Training is based...

2014-03-31 12:29:50

WHITE PLAINS, N.Y., March 31, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society today announced that its Canadian affiliate, The Leukemia & Lymphoma Society of Canada (LLSC), has named Shelagh Tippet-Fagyas as its new president, effective today. http://photos.prnewswire.com/prnvar/20140331/NY94346 Tippet-Fagyas will lead LLSC in its efforts to find cures and ensure access to therapies for all blood cancer patients in Canada. She will be working with the LLSC Board of...

2014-03-28 08:26:35

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera(®)( )(rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in...

2014-03-25 23:31:01

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North Carolina (PRWEB) March 25, 2014 Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. These findings have just been posted on the Non-Hodgkin’s Lymphoma Center at...

2014-03-24 20:23:49

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/7dhkqb/investigation) has announced the addition of the "Investigation Report on China Rituximab Market, 2009-2018" [http://www.researchandmarkets.com/research/7dhkqb/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Rituximab (trade names ""MabThera"" by Roche, ""Rituxan"" by Genetech) is a chimeric...

2014-03-22 23:02:28

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC (PRWEB) March 22, 2014 Scientists studying the Non-Hodgkin’s Lymphoma drug Zolinza (vorinostat) say it may improve outcomes for patients fighting indolent B-cell lymphomas like follicular lymphoma and mantle cell lymphoma. The Phase II study, published in the British Journal of Haematology and reported by the Non-Hodgkin’s...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related